Equity Overview
Price & Market Data
Price: $6.72
Daily Change: -$0.01 / 0.15%
Daily Range: $6.51 - $6.79
Market Cap: $1,096,759,552
Daily Volume: 2,164,971
Performance Metrics
1 Week: -4.34%
1 Month: -13.25%
3 Months: -6.64%
6 Months: -12.68%
1 Year: 66.50%
YTD: -15.80%
Company Details
Employees: 394
Sector: Health technology
Industry: Biotechnology
Country:
Details
Xeris Biopharma Holdings, Inc., a commercial-stage biopharmaceutical company, engages in developing and commercializing therapies for chronic endocrine and neurological diseases in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia in pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It is also developing XP-8121, a once-weekly subcutaneous injection of levothyroxine that is in phase 3 clinical trial for the treatment of hypothyroidism. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.